Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08PLK
|
|||
Drug Name |
Fremanezumab
|
|||
Synonyms |
Fremanezumab [INN]; Fremanezumab [USAN]; UNII-PF8K38CG54; PF8K38CG54; TEV-48125; PF-04472429
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Hyperprolactinaemia [ICD-11: 5A60.1; ICD-10: E22.1; ICD-9: 253.1, 346] | Approved | [1] | |
Company |
Teva
|
|||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Calcitonin gene-related peptide receptor (CGRPR) | Target Info | Modulator | [1] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Vascular smooth muscle contraction | ||||
Reactome | G alpha (s) signalling events | |||
Calcitonin-like ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Endothelin Pathways | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.